ArticleNature microbiology2022
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.
Article in Nature microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 455 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
455 citing papers in PubMed, 3 syntheses or guidelines pooled it, 711 citations in OpenAlex.
- SARS-CoV-2 infection rates and associated risk factors in healthcare workers: systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Saline nasal irrigation and gargling in COVID-19: Part II. Outcomes in Omicron and risk-benefit for self-care.Frontiers in public health · 2025Pooled it
- Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.Human vaccines & immunotherapeutics · 2026Trial
- Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients: A randomized, double-blinded, placebo-controlled phase 2 study.Human vaccines & immunotherapeutics · 2024Trial
- Serology survey against multiple SARS-CoV-2 variants of residents in Tainan, Taiwan.Virulence · 2026Article
- Disulfide bonds stabilize the SARS-CoV-2 RBD and preserve binding to ACE2 following thermal denaturation.Bioscience reports · 2026Article
- A bireporter recombinant SARS-CoV-2 Omicron BA.5 forMicrobiology spectrum · 2026Article
- Raman Analysis of RNA Nucleotide Strands From SARS-CoV-2 Variants and Subvariants: A Step Forward in the Definition of "Raman Genome".Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Seasonal and Age-Stratified Patterns of Influenza, COVID-19, and RSV in Poland (2024-2026).Viruses · 2026Article
- Genomic surveillance of SARS-CoV-2 in Tunisia during the omicron era: insights from the national influenza & other respiratory viruses laboratory.Virology journal · 2026Article
- Discovery of Highly Selective Noncovalent Macrocyclic Peptide Inhibitors Suppressing Both TMPRSS2 Protease Activity and Viral Receptor Function.Journal of medicinal chemistry · 2026Article
- Antiviral activity of Cirsium japonicum var. spinossimum extract and its flavonoid cirsimaritin against human coronavirus OC43.Journal of microbiology (Seoul, Korea) · 2026Article
- metaWEPP: leveraging biobank-scale intra-species phylogenies for near-haplotype resolution in metagenomic analysis.NAR genomics and bioinformatics · 2026Article
- Switching Spike Plasticity Shapes ACE2 Engagement Across SARS-CoV-2 Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells.Journal of virology · 2026Article
- Brain corticogenesis promotes SARS-CoV-2 neuro-glial tropism through lipid-dependent viral replication.Stem cell reports · 2026Article
- Fast and inexpensive visualization of genome collection at scale.BMC bioinformatics · 2026Article
- Viral syncytia evolve to resist interferon.Nature communications · 2026Article
- The impact of ethnicity on longitudinal humoral and cellular immune responses to SARS-CoV-2 booster vaccination.Scientific reports · 2026Article
395 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
43 authors at 20 institutions in 1 country.
Funding
Abstract
Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron (B.1.1.529), the fifth VOC to be described, harbours multiple amino acid mutations in spike, half of which lie within the receptor-binding domain. Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination. The Omicron variants BA.1 and BA.2 did not induce cell syncytia in vitro and favoured a TMPRSS2-independent endosomal entry pathway, these phenotypes mapping to distinct regions of the spike protein. Impaired cell fusion was determined by the receptor-binding domain, while endosomal entry mapped to the S2 domain. Such marked changes in antigenicity and replicative biology may underlie the rapid global spread and altered pathogenicity of the Omicron variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.